Goodwin advised Micropep Technologies, the global leader in micropeptide technology, on its $29 million Series B financing round.
The round was led by Zebra Impact Ventures and BPI Green Tech Investment. All existing investors (Fall Line Capital, FMC Ventures, Sofinnova Partners, Supernova Invest, and IRDI Capital Investissement) also participated.
Micropep Technologies is a global leader in breakthrough micropeptide technology. The company has developed Krisalix, a proprietary AI-powered discovery platform which aims to find new bioactive micropeptides faster and more efficiently than traditional methods. The proceeds from this financing will primarily be used to increase partnerships, complete the regulatory studies of the first biofungicide molecule, and expand its pipeline of micropeptide active ingredients.
The Goodwin team included Anne-Charlotte Rivière and Alex Lecoeur on corporate aspects, and Louis de Chezelles on IP aspects.